The MAFLD was diagnosed by sonographic assessment of hepatosteatosis in 118 (55.4%) patients (F: 56, M: 62), and due to elevated ALT concentration in seven patients (3.3%), without features of liver steatosis in the US exam. This evidence concerns the gene GPT and Hepatic steatosis.